Business Wire Feed
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
Additional research highlights integration of BluePrint molecular subtyping and ImPrint immune profiling to optimize prediction of neoadjuvant treatment response in HER2-positive early-stage breast cancerIRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., a leader in precision oncology for more...
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple myeloma Additional data from the Company’s differentiated pipeline including pumitamig, more...
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical trial evaluations of more...
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
– ASCO Presentations on Trodelvy® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial Launches – – EHA Updates Include Durability of KITE-753, Kite’s Enhanced DuoCore™ more...
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026
Flatiron's real-world evidence research and live Flatiron Telescope demonstrations at booth #21149 showcase how scale and rigor advance oncology decision-makingNEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) more...
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
-- ETX-19477 demonstrated robust efficacy, with a 57% objective response rate in BRCA-mutated platinum-resistant ovarian cancer and earlier-line HR+/HER2- breast cancer (n=7) -- -- Favorable safety profile, including low rates of hematologic toxicity, supports further more...
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral more...
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Noetik’s TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survival In a retrospective analysis of refractory MSS metastatic colorectal cancer without active more...
City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
New findings in kidney, liver and prostate cancers reflect the shift toward more personalized, biology-driven treatment.LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in more...
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit Concordance analysis between MMAI and 21-gene Recurrence Score test in breast cancer SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic more...
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer
Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting provide updates on EVEREST-2 and describe approaches to boost potency and preserve selectivity of TmodTM-based precision cell therapiesCHICAGO--(BUSINESS WIRE)--#ASCO26--A2 Biotherapeutics, Inc. (A2 more...
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in more...
BioVigil Appoints Brad Ryba as Chief Technology Officer to Accelerate Innovation and Market Expansion
ANN ARBOR, Mich.--(BUSINESS WIRE)--BioVigil, the market leader in electronic hand hygiene and infection prevention technology, has hired Brad Ryba as the company’s Chief Technology Officer (CTO). Ryba will lead the company’s technology and data strategy, more...
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment more...
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35%PITTSBURGH & CLEVELAND--(BUSINESS WIRE)--#AI--A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research more...
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet more...
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be presented more...
Diversified Healthcare Trust to Present at Nareit’s REITweek 2026 Investor Conference on Tuesday, June 2nd
NEWTON, Mass.--(BUSINESS WIRE)--Diversified Healthcare Trust (Nasdaq: DHC) today announced that President and Chief Executive Officer Chris Bilotto and Chief Financial Officer and Treasurer Matthew Brown will be presenting at Nareit’s REITweek 2026 Investor Conference in more...
Reimagine Care Expands AI-Enabled Virtual Oncology Model with Moffitt Cancer Center Following Strong Patient and Clinical Outcomes
Initial phase shows sustained patient engagement, reduced acute care utilization and a scalable approach to delivering continuous cancer care beyond the clinicNASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care today announced the expansion of its AI-enabled virtual oncology care more...
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
ALAMEDA, Calif.--(BUSINESS WIRE)--#CRISPR--Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that it has secured clearance more...
Inovalon and Face Rock Enterprises Collaborate to Care for Tribal Health Organizations
Pairing Inovalon’s national-scale data and revenue cycle technology and Face Rock’s deep tribal health expertise to strengthen financial sustainability in underserved tribal communitiesBOWIE, Md.--(BUSINESS WIRE)--Inovalon, a leading provider of data and solutions empowering data-driven healthcare, more...
Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem
Strategic milestone delivers one of the most comprehensive and timely real-world views of community oncology, strengthening Ontada’s portfolio for biopharma partnersBOSTON--(BUSINESS WIRE)--Ontada®, a McKesson business dedicated to real-world oncology data and insights, announced the integration more...
Aramark Healthcare+ Recognized by Modern Healthcare as One of the “Best Places to Work™ in Healthcare” for Third Consecutive Year
PHILADELPHIA--(BUSINESS WIRE)--Aramark Healthcare+ has been named to Modern Healthcare’s “Best Places to Work™ in Healthcare” list for 2026, marking the third consecutive year the organization has earned the recognition. Final rankings will be announced later more...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health’s new FDA-approved liquid biopsy integrates genomic and epigenomic insights to provide a more complete, actionable view of cancer from a simple blood draw Approval strengthens Guardant’s leadership in comprehensive molecular profiling and advances more...
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis
HTX-001 is a first-in-class antisense oligonucleotide designed to downregulate WISPER lncRNA, a driver of fibrosis in the heart Phase 1a/b trial to evaluate the safety and tolerability of HTX-001 in healthy volunteers, followed by patients more...